Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
|ClinicalTrials.gov Identifier: NCT00072553|
Recruitment Status : Unknown
Verified May 2007 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : November 5, 2003
Last Update Posted : February 9, 2009
GERCOR - Multidisciplinary Oncology Cooperative Group
Information provided by:
National Cancer Institute (NCI)
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Primary Completion Date :||No date given|
|Study Completion Date :||No date given|
Publications of Results:
André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, Hebbar M, Postel Vinay S, Bidard FC, Louvet C, de Gramont A; GERCOR (French Oncology Research Group). Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol. 2007 Jan;18(1):77-81. Epub 2006 Oct 9.